Knowledge Hub

At Sterling, we are proud of our heritage, strong technical capabilities and compliance credentials but it’s our people and the genuine and passionate way they do business that makes us different.

Sterling manages the most complex API and API intermediate challenges from proof-of-concept to commercial manufacture, as well as Antibody Drug Conjugate (ADC) research and development bioconjugation services.

At Sterling we believe that whilst science can be complex, partnerships should be simple. That is why we have prepared a range of resources to share our team’s research and expertise, and to help you learn more about Sterling and the services we offer.

Filter Content

Knowledge Hub Articles

Articles

Sterling Pharma Solutions Expands Early Phase Development Capabilities at Cary

Articles

Top 10 early phase considerations

Articles

Sterling Announces Exclusive Partnership with the University of Manchester to Develop Novel Route to Newly Approved COVID-19 Therapy, Molnupiravir